Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

ISSN： 0012-6667

Source： Drugs, Vol.62, Iss.1, 2002-01, pp. : 209-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L. Keam Susan J.

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

By Garnock-Jones Karly P. Keating Gillian M. Scott Lesley J.

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 215-239

Adis International

Access to resources Recommend Favorite

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

Current Drug Targets, Vol. 14, Iss. 8, 2013-07 ,pp. : 889-898

Bentham Science Publishers

Access to resources Recommend Favorite

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Current Cancer Drug Targets, Vol. 15, Iss. 8, 2015-01 ,pp. : 665-683

Bentham Science Publishers

Access to resources Recommend Favorite